Accelerate
Human
Discovery ™
We created Sapient to drive a fundamental shift in today’s costly, slow moving, inefficient drug development process. As a discovery metabolomics lab, we help sponsors and researchers gain a deeper understanding of human biology and use biomarker-guided drug development to effectively align patients, disease, and specific therapies.
Our Platform
Integrated Biomarker Discovery Pipeline
Sapient’s three-pronged platform leverages next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases to enable rapid discovery, population-level validation, and robust translation of small molecule biomarkers.
Accelerated
Drug Creation
High-throughput mass spectrometry technologies perform untargeted profiling of >11,000 small molecule biomarkers per biosample, in <1 minute per sample run.
Analytical Technologies
Data science algorithms and machine learning tools are applied to the data to reveal key biomarkers of biological processes, disease progression, and drug response.
Computational Analysis
Comprised of data from hundreds of thousands of human biosamples, with more than 10-30 years of follow-up data across patients, this repository can be used to cross-validate identified biomarkers.
Human Biology Database
Together these technologies drive significant speed and scale advantages.
Ability to assay
>11,000
small molecule biomarkers per biosample
Capacity to analyze
1,000s
of biosamples per day
